Cellectar Biosciences Inc (CLRB)
3.345
+0.16
(+5.19%)
USD |
NASDAQ |
May 15, 16:00
3.345
0.00 (0.00%)
After-Hours: 16:11
Cellectar Biosciences Free Cash Flow: -33.24M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -33.24M |
| September 30, 2023 | -30.91M |
| June 30, 2023 | -29.26M |
| March 31, 2023 | -27.56M |
| December 31, 2022 | -25.45M |
| September 30, 2022 | -22.56M |
| June 30, 2022 | -21.97M |
| March 31, 2022 | -23.03M |
| December 31, 2021 | -22.71M |
| September 30, 2021 | -21.96M |
| June 30, 2021 | -19.02M |
| March 31, 2021 | -15.23M |
| December 31, 2020 | -14.00M |
| September 30, 2020 | -12.80M |
| June 30, 2020 | -12.84M |
| March 31, 2020 | -12.42M |
| December 31, 2019 | -11.72M |
| September 30, 2019 | -12.16M |
| June 30, 2019 | -11.58M |
| March 31, 2019 | -11.46M |
| December 31, 2018 | -11.83M |
| September 30, 2018 | -11.53M |
| June 30, 2018 | -11.13M |
| March 31, 2018 | -11.50M |
| December 31, 2017 | -11.37M |
| Date | Value |
|---|---|
| September 30, 2017 | -10.96M |
| June 30, 2017 | -10.60M |
| March 31, 2017 | -9.59M |
| December 31, 2016 | -8.354M |
| September 30, 2016 | -7.452M |
| June 30, 2016 | -7.408M |
| March 31, 2016 | -7.698M |
| December 31, 2015 | -8.271M |
| September 30, 2015 | -8.912M |
| June 30, 2015 | -8.840M |
| March 31, 2015 | -8.652M |
| December 31, 2014 | -8.87M |
| September 30, 2014 | -9.408M |
| June 30, 2014 | -9.904M |
| March 31, 2014 | -9.930M |
| December 31, 2013 | -9.302M |
| September 30, 2013 | -8.365M |
| June 30, 2013 | -7.469M |
| March 31, 2013 | -6.947M |
| December 31, 2012 | -6.683M |
| September 30, 2012 | -6.47M |
| June 30, 2012 | -6.392M |
| March 31, 2012 | -7.482M |
| December 31, 2011 | -6.088M |
| September 30, 2011 | -4.660M |
Free Cash Flow Range, Past 5 Years
-33.24M
Minimum
Dec 2023
-11.58M
Maximum
Jun 2019
-20.02M
Average
-21.96M
Median
Sep 2021
Free Cash Flow Benchmarks
| Perspective Therapeutics Inc | -37.98M |
| Eli Lilly and Co | -3.896B |
| Actinium Pharmaceuticals Inc | -39.72M |
| Bristol-Myers Squibb Co | 12.51B |
| Altimmune Inc | -75.86M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -9.596M |
| Cash from Investing (Quarterly) | -0.2668M |
| Cash from Financing (Quarterly) | 0.441M |
| Free Cash Flow Per Share (Quarterly) | -0.6551 |
| Free Cash Flow Yield | -81.31% |